Case report describes the use of peritoneal dialysis in a patient with ESKD from transthyretin amyloidosis, highlighting management difficulties.
Amyloidosis is a disease characterized by extracellular deposition of misfolded proteins, causing progressive organ damage, including end-stage kidney disease (ESKD). Patients with ESKD due to amyloidosis face poor survival rates, and evidence to guide optimal management strategies is lacking. We present the case of a 64-year-old woman with hereditary transthyretin (TTR) amyloidosis and ESKD who has been successfully treated with peritoneal dialysis (PD) for over 33 months. This report highlights the challenges encountered during follow-up, including the progression of peripheral neuropathy, and underscores the need for further investigation leading to targeted therapies to prevent disease progression and complications.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: